XtalPi scores landmark deal for AI drug discovery
The biotech has partnered with U.S. firm DoveTree in a collaboration worth up to $5.99 billion, adding to a slew of major deals for Chinese research firms this year Key…
InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
RELATED ARTICLES
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK -
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BRIEF: XtalPi acquires British chiral molecule developer
2228.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
